Immunopathological features of air pollution and its impact on inflammatory airway diseases (IAD)

Philip W. Rouadi*, Samar A. Idriss**, Robert M. Naclerio, David B. Peden, Ignacio J. Ansotegui, Giorgio Walter Canonica, Sandra Nora Gonzalez-Diaz, Nelson A. Rosario Filho, Juan Carlos Ivancevich, Peter W. Hellings, Margarita Murrieta-Aguttes, Fares H. Zaitoun, Carla Irani, Marilyn R. Karam and Jean Bousquet

ABSTRACT

Air pollution causes significant morbidity and mortality in patients with inflammatory airway diseases (IAD) such as allergic rhinitis (AR), chronic rhinosinusitis (CRS), asthma, and chronic obstructive pulmonary disease (COPD). Oxidative stress in patients with IAD can induce eosinophilic inflammation in the airways, augment atopic allergic sensitization, and increase susceptibility to infection. We reviewed emerging data depicting the involvement of oxidative stress in IAD patients. We evaluated biomarkers, outcome measures and immunopathological alterations across the airway mucosal barrier following exposure, particularly when accentuated by an infectious insult.

Keywords: Inflammatory airway disease, Air pollution, Oxidative stress biomarkers, Tobacco smoke, Antioxidant

INTRODUCTION

The presence in the air of one or more natural or anthropogenic substances at a concentration, or location, for a duration, above their natural levels with the potential to cause an adverse health effect defines air pollution. Indoor air pollution refers to chemical, biological, and physical exposure of air pollutants in homes, schools, and workplaces.

Similar to indoor air pollution, ambient (outdoor) air pollution can result from chemical substances or biologically derived contaminants modified by climate change or human activity such as bioaerosols and aeroallergens. Air quality guidelines endorsed by the World Health Organization (WHO) aim to provide clean air in and around the home. Air pollution reduced life expectancy in 2017 by 1 year and 8 months on average worldwide. WHO has linked 4.3 million deaths globally in 2012 to household cooking using coal, wood and biomass stoves. Outdoor air pollution in the same year caused an estimated 3.7 million deaths.

In inflammatory airway disease (IAD) patients an estimated 7-11% increased risk in asthma-related mortality was commensurate with a rise in ambient pollutant concentrations such as NO2, PM2.5, or ozone when computed few days prior to asthma death. Similar but smaller increments in chronic...
obstructive pulmonary disease (COPD)-related mortality were attributed to pollution and ranged from 0.78% to 1.78%.

In the respiratory tract, air pollution can impact wellness in healthy people and patients with IAD, irrespective of their atopic status. Hence, the airway mucosal barrier may be disrupted by immunopathological mechanisms resulting from effects of pollution and IAD. The co-occurrence of IAD phenotypes (allergic rhinitis, and chronic rhinosinusitis, COPD and asthma) within an individual increases the likelihood of pollutant induced exacerbation of disease or infection.

We reviewed the following IADs in relation to air pollution. Allergic rhinitis (AR), is an IgE mediated inflammatory disease generated by a spectrum of outdoor aeroallergens like pollens or indoor aeroallergens such as dust mites, cockroaches, cat allergens, or molds. CRS represents multiple overlapping rhinosinusitis phenotypes with different endotypes. Asthma is characterized by chronic atopic or non-atopic inflammation of the airway with superimposed episodes of acute exacerbations. The majority of exacerbations are triggered by respiratory viral infections, most commonly human rhinovirus. Other triggers include allergens and atmospheric pollutants.

COPD, another chronic inflammatory airway disease, is characterized by airflow limitation and cough. Acute exacerbation of COPD, like in the upper airway, can be triggered by infection and inhalation of irritants.

**CHARACTERISTICS OF AIR POLLUTANTS**

Chemical pollutants are health-damaging atmospheric aerosol and non-aerosol particles originating from a variety of natural (eg, volcanic eruptions) or anthropogenic sources (eg, biomass burning, fossil fuel combustion, or traffic related particles). Primary pollutants such as particulate matter (PM) and volatile organic compounds are aerosol particles directly emitted as solid or liquid droplets in the air. In the atmosphere, natural gas-to-particle conversion can culminate in secondary chemical pollutant particles like ozone and PM.

**Particulate matter and nanoparticles**

Particulate matter (PM) is a mixture of solid and liquid particles suspended in indoor and outdoor air. Their source, size, classification, and airway distribution patterns are well described. Various human indoor activities cause resuspension and deposition of particles in indoor air, a process governed primarily by the effective size of the particle. This can range from hours for PM$_{10}$ to several months for 2-μm particulate pollutants. PM$_{2.5}$ broadly represents around 50% of the total mass of PM$_{10}$ and can be inhaled more deeply into the lungs, with a portion depositing in the alveoli and entering the pulmonary and systemic circulation. The submicron PM family, ultrafine particles and nanoparticles, due to their small size, have a relatively large surface area allowing a greater proportion of compounds to be displayed at the surface such as metals and organic compounds. They cannot be taken by macrophages and can escape phagocytosis. When retained in the lungs, the ensuing inflammation can result in asthma and lung fibrosis; yet they can allocate to distant organs through systemic circulation resulting in different toxicological phenotypes such as diabetes and heart disease. The adverse health effects of PM are not uniform since PM is not a single entity; rather its constituents and their proportion in ambient air can change from one geographical location to another depending on the type of emissions inherent to each area.

**Volatile organic compounds (VOCs) and formaldehyde**

VOCs are primary pollutants located mainly indoors and include benzene, toluene, xylens, terpenes, and polycyclic aromatic hydrocarbons. They produce a secondary pollutant, formaldehyde, by an indoor chemical reaction between ozone or nitrogen oxide and terpene. Formaldehyde appears to be associated with a higher risk of nasopharyngeal carcinoma and leukemia. The primary domestic, microbial, and socio-cultural sources of VOCs are well elaborated.
Diesel exhaust particles (DEP)

Diesel exhaust represents the most important local contributor to ambient air pollution and has been classified by WHO as carcinogenic to humans. It is a complex mixture of chemicals and metals stratified into 3 fractions: a solid fraction (made of a soot of carbon core, metals, and their oxides), a gaseous fraction (made of nitrogen, oxygen, and polycyclic aromatic hydrocarbons - PAHs), and a liquid fraction where PAHs can adsorb into soot or water droplets. Ultrafine particles, nitrogen oxide, and PM (in the range of 2.5 μm) can be produced also by internal combustion of diesel engines. Metal elements include Chromium, Magnesium, Zinc, and Lead and are associated with engine emissions and abrasion of tires and brake pads. Vanadium and Nickel are tracers of long-range transport from the use of heavy fuel oil. The relatively large surface area of diesel exhaust particles (DEPs) permits many of these chemicals and metals to attach to its core. Thus, most of the deleterious effects of DEPs are due to chemicals that are adsorbed onto their surface.

Ozone and nitrogen oxide (NOx)

To date, ozone is considered the most damaging air pollutant in terms of adverse effects on human health, vegetation, and crops. It produces short- and long-term effects on cardiorespiratory function. Recent evidence suggests there is no threshold concentration below which there are no effects on health. Ground-level ozone is formed in the atmosphere by a complex reaction of its precursors, nitrogen oxide (NOx), carbon monoxide, and volatile organic compounds in the presence of sunlight. Background ozone concentrations are strongly correlated with the increased global NOx emissions derived from human-generated fossil fuel combustion and biomass burning.

Tobacco smoke (TBS)

Tobacco smoke (TBS) emits a wide range of gases, aerosolized liquids, and fine particulate matter including VOC and formaldehyde, nitrogen oxide, PM2.5, and nicotine. TBS is estimated to cause approximately 480,000 excess deaths per year, and it can contribute to 30% of all cancer deaths. Among other actions, TBS can induce DNA damage, change in sputum (mucin) quality, and depressed antioxidant and antimicrobial activity in smokers and among COPD patients.

Household dust

Household dust represents a convenient means to sample respiratory exposure to pollutants. In one study, the respirable fraction of dust constituted less than 1% of the total weight of dust surrounding us, and on scan electron microscopy consisted of large flakes (>20 μm diameter) to which are adherent smaller particles. The median aerodynamic diameter of respirable dust particles allows their deposition both in the nose and lungs. The chemical composition of these flakes suggests household dust might be an important carrier vehicle of organic pollutants into the airways in addition to its intrinsic risk of oxidative stress.

Types and aerodynamics properties of allergens

Allergens can pollute indoor and outdoor air and exacerbate AR and asthma. Indoor allergenic pollutants can be derived from skin scales of pets (eg, cats, dogs), urine of rodents (eg, mice), molds, or from fecal material of arthropods such as house dust mites and cockroaches. Outdoor allergens are aeroallergens originating from grasses, trees, weeds, or molds. Outdoor pollen also modulates indoor aeroallergen concentration. The concentration of aeroallergens in the indoor environment is governed by complex bioaerosol dynamics. For example, airborne cat allergen (Fel d1) is mostly associated with large particles (>9 μm), but around 1/4 of Fel d1 are carried on particles less than 4 micra in diameter. Thus Fel d1 can be deposited in the alveoli but most importantly suspended for several days in the air favoring distribution of the allergen in the environment. Also, the 33 groups of mite allergens listed in the WHO nomenclature of allergens are composed of particles ranging in diameter from 10 to 40 μm. Hence, they can become airborne upon disturbance and can be carried on house dust that becomes a vector for exposure. How dust mite allergen particles can induce and
trigger asthma in lower airways remains to be determined.\textsuperscript{62}

**INFECTIOUS PARTICLES**

The diversity and functioning of the normal microbiome are crucial for maintaining the health of the host. While the effects of PM on human health are well established, the impact of infectious particles on bacterial ecosystems has been overlooked.

*In vitro* studies suggest black carbon, a major component of PM, is strongly implicated in predisposition to respiratory infectious diseases,\textsuperscript{25,63} and induces structural and functional changes in the biofilms of both *Streptococcus pneumonia* and *Staphylococcus aureus*.\textsuperscript{64} This is manifested by increase in biofilm thickness and tolerance to degradation by proteolytic enzymes, thereby promoting colonization of the respiratory tract. Similarly, evidence suggests indoor and outdoor dust modifies microbial growth, virulence, and biofilm formation of opportunistic pathogens. By exposing 3 opportunistic bacteria (*Pseudomonas aeruginosa, Escherichia coli, and Enterococcus faecalis*) to progressively increasing concentrations of indoor and outdoor dust, a differential growth pattern of pathogens was noted. This was commensurate with increased biofilm formation and sensitivity to oxidative stress following hydrogen peroxide challenge.\textsuperscript{65} Consequently, the detrimental impact of particulate pollutants on human health is not only due to direct effects on the host but also may involve the effect on bacterial behavior in the host.

**COMPARATIVE ANALYSIS OF OXIDATIVE STRESS-MEDIATED IMMUNOPATHOLOGICAL ALTERATIONS IN CLINICAL MODELS OF IAD**

Oxidative stress is a disproportionate generation of free radicals beyond the body antioxidant capacity. It translates into a non-IgE mediated Th2 airway inflammation following exposure to a pollutant. In brief, reactive oxygen species (ROS), generated naturally as by-product of cell growth and metabolism, can be produced following pollutant exposure.\textsuperscript{66,67} ROS include oxygen radicals (eg, superoxide, hydroxyl, hydroperoxyl) and certain non-radicals (eg, H\textsubscript{2}O\textsubscript{2}, ozone, singlet oxygen) that are easily converted into radicals.\textsuperscript{68} ROS have a pivotal role in cell signaling in the oxidation/reduction cascades following exposure and ultimately generation of anti-oxidant mechanisms thru nrf-2, activator protein 1, and nuclear factor-kappa B.\textsuperscript{69–72} Antioxidants are scavengers of ROS and can be enzymatic or non-enzymatic systems, constitutive or de novo synthesized by activated gene expression, according to ROS load. The inflammatory phase of oxidative stress involves cytokines- and chemokines-mediated activation and recruitment of inflammatory cells secondary to direct effect of pollutants on airway epithelial cells.\textsuperscript{67} This can propagate oxidative stress further and augment the inflammatory response and tissue damage.\textsuperscript{73} Alternatively, ROS can contribute directly to cell injury and apoptosis by disrupting cellular and nuclear membranes in the epithelial barrier wall and altering the function of cellular enzymes.\textsuperscript{74,75} A different mechanism by which environmental pollution can trigger disease in the nose is via a neurogenic mechanism.\textsuperscript{76} Another component of oxidative pathway is the exposure-driven adjuvant effect on atopy where environmental pollution acts as an exacerbating factor for allergic airway disease by enhancement of allergic airway hypersensitivity in atopic individuals. The evidence emerges from experimental protocols involving inhalation of pollutants and allergen challenge which show pollutants can act synergistically to heighten the allergic response with increased expression of Th2 inflammatory biomarkers.\textsuperscript{76,77} This is in contrast to healthy individuals which express either Th1 or a mixed Th1/Th2 profile in controlled exposure studies.\textsuperscript{78}

Epidemiological studies suggest pollution modulates AR,\textsuperscript{79–85} rhinosinusitis,\textsuperscript{86} and asthma.\textsuperscript{85,87} Other studies suggest a positive association between exposure and prevalence of AR and asthma\textsuperscript{83,88–91} in children and adults predominately in reports on short-term exposure\textsuperscript{88} and residential proximity studies to sources of traffic pollution.\textsuperscript{87,92} However, other long-term exposure studies provided evidence to the contrary.\textsuperscript{93–95} This could be due to differences in study design, methods of exposure assessment, and complex nature of studied pollutants.\textsuperscript{79,80,82,92}
| Author/Year | Clinical Model | Group under study | Outcome measure/Biomarkers | Clinical Findings |
|-------------|----------------|-------------------|----------------------------|-------------------|
| Elhini A, 2006 | Human In-vivo | Perennial AR | Inferior turbinate: - HO-1 and HO-2 isoenzyme antioxidant mRNA expression | Upregulated expression of nasal cytoprotective stress response markers, HO-1, but not HO-2, in perennial allergic diseases. |
| Gratziou C, 2008 | Human In-vivo | SAR/Allergic asthma | Exhaled breath air and condensate variation with pollen season and INS therapy - eNO; Iso-8 (lipid peroxidation marker), LTB4; Nitrate/Nitrite | Compared to healthy subjects, increased all OS markers in (SAR) patients during natural allergen exposure irrespective of asthma comorbidity; compared to patients with SAR only, eNO and nitrates more pronounced in patients with concomitant asthma. Iso-8 and LTB4 but not nitrate/nitrite are reduced with nasal steroids suggesting a regulatory role in OS response. |
| Moon J, 2009 | Human In-vivo | AR or CRSwNP | Inferior turbinate and nasal polyps: - NOX1 and NOX4 antioxidant levels and mRNA expression | Increased NOX-1 and -4 levels and mRNA expression in allergic nasal mucosa and nasal polyps mediated by ROS-generating NADPH oxidase suggest their role in pathogenesis of AR and CRSwNP. |
| Sadowska-Woda I, 2010 | Human In-vivo | Perennial AR in children | Blood erythrocytes analysis with desloratadine therapy: - Catalase and superoxide dismutase (antioxidant enzymes), malondialdehyde (lipid peroxidation marker) | Reduction in antioxidant enzyme (catalase and superoxide dismutase) activity and malondialdehyde level and reversal with desloratadine suggest OS is implicated in pathogenesis of PAR and desloratadine can exert an antioxidant effect |
| Sagdic A, 2011 | Human In-vivo | Allergic and non-allergic asthma, AR | Blood erythrocyte analysis: - CuZnSOD and GSH-Px antioxidant enzyme activity; malondialdehyde (lipid peroxidation marker) | Decreased CuZnSOD enzyme activity but not GSH-Px and MDA in allergic and non-allergic asthma and AR suggest OS mediates inflammation in rhinitis and asthma, irrespective of atopic status. |
| Celik M, 2012 | Human In-vivo | Allergic asthma and rhinitis in children | Nasal and oral exhaled breath condensate with topical steroid therapy: | Decrease in GSH antioxidant enzyme level and increase in MDA oxidative biomarker in both | (continued) |
| Author /year | Clinical Model | Group under study | Outcome measure/ Biomarkers | Clinical Findings |
|-------------|---------------|------------------|----------------------------|-------------------|
| Cho DY, 2012 | Human In-vivo | CRSwNP and CRSsNP | Nasal polyp, tissue and lavage: - Cytokines (Eotaxin, monokine-induced by IFN-γ -MIG, TNF-α, and IL-8) and H₂O₂ (released into mucosal fluid layer); DUOX1 and DUOX2 (NADPH oxidase) mRNA expression and protein level | Increased level of DUOX1 and DUOX2 in nasal polyps positively correlate with cytokine levels of eotaxin, MIG and TNF-α; also increased level of DUOX2 but not DUOX1 in nasal tissue of CRSsNP positively correlate with H₂O₂. Findings suggest OS can differentially modulate different CRS phenotypes in terms of DUOX -1 and -2 antioxidant enzyme level and expression. |
| Emin O, 2012 | Human In-vivo | Perennial AR in children | Blood analysis: - Plasma total oxidant status (TOS); total antioxidant status (TAS); total serum IgE levels; skin sensitization | Increased TOS and decreased TAS is independent of total IgE levels and allergic sensitization in children with PAR. |
| Guibas G, 2013 | Rat In- vivo | Ova-sensitized rats | Sinonasal tissue and blood with NAC and Ova challenge: - Tissue eosinophil and mast cells; iNOS and COX2 mucosal expression; and serum TNF-α | Following Ova challenge, upregulated count of eosinophils and mast cells, mucosal expression of iNOS, COX-2, and TNF-α level and their downregulation by NAC (except for COX2 expression) suggest important antioxidant property of NAC in allergic reactions and a diverse role of COX2 in redox sensitive reactions. |
| Ozkaya E, 2013 | Human In-vivo | Perennial AR in children | Blood analysis: - Plasma PON1 (antioxidant enzyme activity) and TOS; total serum IgE level; Nasal symptoms score | Nasal symptom scores correlate negatively with serum PON1 and positively with TOS levels and hence serve as predictors of disease severity in children with AR, independently of total IgE levels. |

(continued)
| Author /year | Clinical Model | Group under study | Outcome measure/ Biomarkers | Clinical Findings |
|--------------|----------------|-------------------|-----------------------------|-------------------|
| Yu Z, 2015[^97] | Human In-vivo | Eosinophilic and non-eosinophilic CRS with nasal polyps | Nasal Polyp (NP): - HO-1 and HO-2 (antioxidant) enzymes mRNA expression and protein level. | Increased HO-1 and HO-2 expression in nasal polyps, more so for HO-1 expression in non-ECRS compared to ECRS; their induction by cytokines and inhibition by TGF-β1 suggest a differential role of HO-1 in different endotypes of nasal polyps. |
| Chan TK, 2016[^75] | Mice and human In-vivo | Asthmatic HDM-sensitized mice | Mice BAL +/-or LT following HDM challenge; or BEAS or asthmatic patients: - Neutrophil, Eosinophil, Mφ, Total T cell counts; 8-IP, 3- NT, 8-OG (markers of oxidative damage to lipids, proteins and nucleic acids, respectively); γ H2AX [DNA DS breaks marker-DSB] positive cells, Rad51, Ku70, PARP-1 and PAR (DNA repair pathway marker); NU7441 (DNA DSB repair inhibitor); IL-4, IL-5, IL-13, IL-33 production; Apoptosis in situ and in vitro | HDM challenge triggered an ROS-mediated induction of DNA damage (γ H2AX) in healthy or asthmatic humans and mice; in challenged mice recruitment of inflammatory cells and upregulation of markers involved in oxidative damage to lipids, proteins and nucleic acids (8-IP, 3-NT, 8-OG); in all three groups induction of DNA repair proteins. HDM challenge and administration of DNA repair inhibitor (NU7441) induces DNA repair markers (Rad51, Ku70, PARP-1 and PAR) in asthmatic patients and HDM-challenged mice concomitant with increased cytokines (IL-4, IL-5, IL-13, IL-33) and Annexin V/P staining in BEAS; all suggesting the importance of DNA repair in protection against HDM exposure-induced cell apoptosis and in suppressing airway inflammation in-vitro. |
| Ulusoy S, 2016[^110] | Human In-vivo | SAR | Blood analysis with pollen season: Thiol-SH (antioxidant marker) level, disulfide-SS (oxidative stress marker) level, and total SH (TT) level | Decreased levels of thiol-SH and increased levels of disulfide-SS during exacerbations of SAR compared to asymptomatic period suggests natural allergen exposure reverses oxidative and anti-oxidative status in SAR, which are not completely abolished even outside pollination season (continued) |
In vivo studies in both human and animal models suggest pollutant exposure induces inflammatory changes in normal, chronically diseased and allergic nasal and sinonasal tissues (Table 1). The cytokine profile of affected tissues suggests activation of the oxidative inflammatory pathways. Moreover, there is compelling evidence for involvement of oxidative stress inflammatory pathways following pollutant exposure in the pathogenesis of rhinitis, CRS, and asthma irrespective of atopic status. This stems from an abundance of literature on oxidative stress biomarkers studied under natural or experimental allergen exposure both in seasonal and perennial AR described in Table 1. In fact, dust mite or ragweed allergic patients exposed to diesel exhaust particles DEPs in climate chamber expressed higher nasal symptom scores following dust mite or ragweed challenge, respectively, when compared to non-exposed but allergen-challenged patients. Also in the lower airways, short-term natural increase in ambient air ozone was associated with deteriorating lung function tests in atopic asthmatics despite use of proper asthma controller therapy. Similarly, an ozone exposure protocol revealed atopic asthmatics expressed depressed spirometry testing results compared to healthy volunteers. Along with this, climate chamber studies revealed (ozone) exposure of healthy or allergic asthmatics induces a neutrophilic or a mixed neutrophilic and eosinophilic inflammatory profile in the lower airways, respectively. Furthermore, gene expression profiles of sputum cells recovered from healthy volunteers and allergic asthmatic patients also confirmed significant difference in inflammatory response to ozone exposure.

Analysis of biomarkers activity greatly improved our understanding of cascade and signal pathways involved in atopic and non-atopic phenotypes of airway disease following exposure. Although most oxidative stress biomarkers require tissue specimen collection, some studies suggest an analysis of biomarkers can be determined non-invasively in

| Author/year | Clinical Model | Group under study | Outcome measure/ Biomarkers | Clinical Findings |
|-------------|----------------|-------------------|----------------------------|-------------------|
| Hong Z, 2016 | Human In-vitro | PM2.5 | NEC with pollutant exposure and NAC administration: Cell viability, Reactive oxygen species (ROS); Antioxidant enzyme activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px); nuclear translocation of NF-E2-related factor-2 (Nrf2) (protector from oxidative stress); Levels of cytokines and respective mRNA expression of GM-CSF, TNF-α, IL-13, eotaxin, IL-6 and IL-8 | Pollutant exposure decreased cell viability and antioxidant enzymes levels in parallel with increased ROS levels, cytokines expression and important Nrf2 protective activity; overall effect reversed by NAC treatment. |
exhaled breath condensates or blood.\textsuperscript{106-111} Natural allergen exposure reverses oxidative and antioxidative status compared to asymptomatic period, with a persistent oxidative state outside pollination season in allergic patients when compared to healthy controls. AR and asthma comorbidity in children does not seem to augment oxidative stress markers compared to AR alone,\textsuperscript{111} although adult patients with seasonal AR and asthma manifest an exaggerated stress response during natural allergen exposure compared to AR alone.\textsuperscript{106} Clinically, oxidative stress correlates with nasal symptom scores in children with perennial AR and can predict AR severity independent of total IgE.\textsuperscript{109} Additionally, ROS status does not correlate with atopic skin sensitization in children with perennial AR.\textsuperscript{108} Furthermore, dust mite challenge in asthmatics or sensitized mice resulted in oxidative damage to nucleic acids as well as lipids and proteins and subsequently triggered DNA repair pathways. Further blockage of DNA repair proteins resulted in increased production of DNA double-strand breaks and cell apoptotic enzymes suggesting importance of DNA repair in suppressing airway inflammation.\textsuperscript{75}

Endogenous antioxidant response in atopic respiratory diseases is complex and oxidative stress response to anti-inflammatory drugs isare poorly understood. Antioxidant enzymes mostly studied in atopic respiratory diseases include heme oxygenase-1 and 2,\textsuperscript{112} NADPH oxidases,\textsuperscript{113} catalase,\textsuperscript{98,114} superoxide dismutase,\textsuperscript{98,107,114} dual oxidases 1 and 2 (in CRS patients),\textsuperscript{96} paraoxonase,\textsuperscript{109} and glutathione peroxidase.\textsuperscript{98,111} Antioxidant activity can also be measured by serum thiol-SH and total antioxidant status (Table 1). In this respect, evidence suggests oxidative stress decreases antioxidant enzyme activity or total antioxidant status in atopic children\textsuperscript{108,109,111} or in human in vitro controlled exposure studies,\textsuperscript{98} whereas other studies present evidence to the contrary. For example, heme oxygenase antioxidant (iso)enzyme-1 activity was preferentially increased in a human in vitro model of perennial AR,\textsuperscript{112} and upregulated in a human exposure model of COPD aggravated by infection;\textsuperscript{115} also dual oxidase antioxidant (iso) enzymes showed preferential upregulation in different phenotypes and endotypes of CRS.\textsuperscript{96,97} Contrary to this, antioxidant enzymes can be downregulated in asthma and rhinitis irrespective of atopic status,\textsuperscript{107} and in vitro animal exposure models challenged by an infectious insult.\textsuperscript{72} Importantly, genetic polymorphism in antioxidant/detoxifying genes like GSTM1 and GSTP1 can alter oxidative stress response in patients with COPD and those with AR following exposure.\textsuperscript{116,117}

Exogenous (dietary) antioxidants are scavengers of oxygen free radicals and can act on different levels of defensive antioxidation pathways.\textsuperscript{118,119} Epidemiologic,\textsuperscript{120} in vivo\textsuperscript{121,122} and in vitro\textsuperscript{123} studies suggest a beneficial role of exogenous antioxidants in patients with IAD or in controlled exposure studies of healthy sinonasal epithelial cells. However, lack of clinical trials data clearly supporting their efficacy, in addition to their potential role in skewing Th1/Th2 balance towards a Th2-type immunity as suggested in vitro,\textsuperscript{124} renders their indication restricted to special situations such as over exposure to environmental pollutants, among others.\textsuperscript{125} N-acetylcysteyne maintains a potent antioxidant effect in in vitro studies\textsuperscript{98} or in ovalbumin-sensitized rats by downregulating tumor necrosis factor-alpha in recruited inflammatory cells.\textsuperscript{126} Along these lines, intranasal steroids can exhibit an exogenous antioxidant regulatory role in seasonal AR by decreasing exhaled breath condensates of leukotriene B4 and 8-Isoprostane, although no effect was seen on exhaled carbon monoxide and nitrogen oxide.\textsuperscript{106} In another study involving children with AR and asthma, no effect of topical nasal steroid therapy was noted on measured lipid peroxidation oxidative stress biomarkers and antioxidant enzymes.\textsuperscript{111} Data on potential antioxidant effect of inhaled steroids in adult asthmatics is scarce. Epidemiological studies suggested prior intake of oral\textsuperscript{127} or inhaled steroids\textsuperscript{128} in adult asthmatic patients had no effect on asthma control, as measured by clinical symptoms and FEV1 testing, with PM and ozone exposure. Other similar studies noted increased consumption of asthma controller therapy (bronchodilators, inhaled corticosteroids, or both) with PM10\textsuperscript{129} or NO2 exposure\textsuperscript{130} in adults. Moreover, in children inhaled steroid therapy downregulated induced expression of heme oxygenase-1 in non-smoking patients with
bronchiectasis but had no effect on exhaled carbon monoxide. Furthermore, desloratadine can exert an antioxidant effect in children with perennial AR by increasing antioxidant enzyme activities (catalase and superoxide dismutase) and decreasing lipid peroxidation marker (malonaldehyde) although no effect was seen on total antioxidant status. When compared to placebo, fexofenadine improved nasal symptom scores in ragweed AR patients following ragweed challenge and DEP controlled exposure.

The majority of controlled human exposure studies to ambient pollutants have been conducted in climate chambers on healthy individuals. For example, relative to clean air, mixtures of VOCs increased ratings of nasal irritation, odor intensity and cognitive symptoms (memory loss, dizziness), and a two-fold increase in polymorphonuclear cells in nasal lavage immediately following exposure. Similar studies using different pollutants showed no detectable effects on nasal symptom scores or markers of nasal inflammation. Additionally, healthy subjects exposed to room air, nanoparticles, or O₃/terpene showed no significant changes in inflammatory biomarkers in blood, sputum or nasal secretions and pulmonary function tests. However, only nanoparticles exposure increased significantly high frequency variability in heart rate, thereby indicating a shift in autonomic balance to a more parasympathetic tone. Low level ozone exposure in healthy subjects resulted in increased sputum production of airway inflammatory cells such as neutrophils, monocytes, and dendritic cells, and modification of cell surface phenotypes of antigen presenting cells. Using a similar protocol the reported decrement in lung spirometry testing (FEV1) of healthy subjects was associated with increased neutrophilic airway inflammation following exposure; the latter likely being more pronounced in healthy individuals with GSTM1 null genotype. More importantly, comparing healthy controls to atopic asthmatics, exposure to high levels of ultrafine particles in a climate chamber was associated with a small but significant fall in arterial oxygen saturation, a fall in forced expired volume over 1 s (FEV1) the morning after exposure, and a transient slight decrease in low frequency (sympathetic) power during quiet rest. These controversial results can be related partly to the nature and concentration of the investigated pollutant or its experimental duration of exposure keeping in mind brief exposure to a single pollutant in a climate chamber does not reflect chronic exposure to multiple pollutants in real life. Controlled exposure studies in atopic patients involving allergen challenge revealed more consistent results. For example, dust mite allergic patients reported worsening nasal symptom scores following intranasal dust mite challenge and DEP exposure commensurate with increased histamine levels in nasal washes, all suggestive of induced mast-cell degranulation. Similarly, controlled exposure studies in ragweed allergic patients challenged with DEP and ragweed outside their pollen season reported higher total nasal symptoms scores or increased levels of specific IgE and expression of Th2 inflammatory cytokines, when compared to ragweed challenged alone.

Taken together, controlled airway exposure studies to ambient pollutants in healthy individuals show small but significant negative health effects whereas exposure studies in allergic patients support the role of pollutants in increasing atopic airway hypersensitivity. Large scale translational studies are needed to correlate the bio-cellular toxic effects of pollution with epidemiological studies.

**COMPARATIVE ANALYSIS OF IMMUNOPATHOLOGICAL ALTERATIONS IN CLINICAL EXPOSURE MODELS OF IAD ACCENTUATED BY INFECTION**

Signal and cascade pathways triggered across the airway mucosal barrier at first encounter of pollutants are complex (see Fig. 1). Airway mucosal cells can recognize pollutants through an epithelial toll-like receptors (TLR)-mediated mechanism either directly or indirectly by the intermediary of pattern recognition receptors (see below). More precisely, pollutants such as PM, cigarette smoke, and ozone can present themselves directly to subclasses of surface TLRs, namely TLR2 and TLR4, which can serve as ligands for these pollutants. Alternatively, pollutants can be bound to pattern recognition receptors, a
collective conglomerate of receptors which encompasses TLRs and normally can recognize conserved molecular structures derived from microbial agents or released by damaged non-microbial cells. Once triggered, pattern recognition receptors and TLRs attract antigen presenting cells and leukocytes to the site of inflammation resulting in priming of the airway to subsequent mucosal infectious insults. Afterwards, when eventuated by an infectious challenge, alveolar macrophages mount a heightened inflammatory response aimed at containing and clearing bacteria while producing minimal collateral tissue damage. The immunological “storm” resulting from co-exposure and infection is studied in different clinical models of respiratory cells and also in patients with IAD such as COPD (Table 2). Another signal pathway is mediated by submucosal innate lymphoid cells (ILCs) which can differentiate into adaptive subsets. ILC1s relates to immune reactions in CRS without nasal polyps, COPD, and some viral and bacterial infections; whereas ILC2s becomes important in regulating type 2 immunity and some helminthic and viral infections. Other immunologic and antimicrobial responses to pollutant exposure modulate expression of host defense peptides and antiviral mechanisms, impair mucus production crucial for capturing pollutants or weaken tight junctions essential for the epithelial airway defense barrier.

Epidemiological studies suggest indoor and outdoor air pollution increase the risk of respiratory tract infections in both pediatric and adult populations. For example, morbidity of the recent COVID-19 pandemic disease has been linked partly to air pollution. Also, air pollution can aggravate the severity of asthma caused by respiratory viral infections. Moreover, in vitro studies suggest air pollution may suppress innate and adaptive immunity and increases susceptibility to bacterial and viral respiratory infections in both human and animal clinical models, following short- or long-term exposure (see Table 2). For example, in the upper airways diesel exhaust exposure increased the number of human nasal epithelial cells infected by Influenza A virus in vitro. The proposed mechanism was enhancement of virus attachment and entry into respiratory cells mediated by radical oxygen species, despite increased antiviral interferon-dependent signaling and interferon-stimulated gene expression by DEP exposure. Also, in vitro Rhinovirus (RV) 16 infectivity following nitrogen oxide and ozone exposure in human respiratory epithelial cells.
| Author, year | Clinical Model | Sample under study | Pollutant | Infectious agent | Outcome measure | Clinical Findings |
|-------------|----------------|--------------------|-----------|-----------------|-----------------|-------------------|
| Yang H, 2001 | Rats | LT & BALF | DEP | LM | LT and BALF, MΦ following exposure and infection: - ROS formation; NO level; CD4 and CD8, CD4\(^+\)/CD8\(^+\) T cells & MΦ | DEP exposure in rats increases susceptibility to LM infection by attenuating MΦ function (ROS and NO production) and T cell (CD4 and CD8) mediated immunity. |
| Spannhake W, 2002 | Human | NEC & BEC | NO\(_2\) & O\(_3\) | RV16 | BEC, following infection and exposure: - IL-8 release (neutrophil chemotactic factor, phagocytosis stimulant); ICAM-1 (receptor for human RV 16- Epithelial surface inflammatory binding protein) mRNA expression | Pollutant-induced exaggerated RV16 infectivity manifested by upregulation of ICAM-1 and increased binding to airway epithelial cells and mediated by induction of proinflammatory IL-8 cytokines production and oxidative stress pathway |
| Yin X, 2004 | Rats | LT & BALF | DEP | LM | BALF and LT, following exposure and infection: - LPS-assisted AM IL-1\(\beta\) (acts on NK cell), TNF-\(\alpha\) (acts on NK cell), IL-12 (initiator of cell mediated immunity), IL-10 (immunosuppressive cytokine and prolongs intracellular pathogens survival- e.g. LM), IL-2, IFN-\(\gamma\) (released by NK), and IL-6 (induction of cytotoxic T lymphocyte development from murine thymocytes); Lung draining lymph node CD4\(^+\)/CD8\(^+\) T cells | LM-mediated suppression of innate (i.e. MΦ, IL-1\(\beta\), TNF-\(\alpha\), IL-12, IL-2 and IFN-\(\gamma\)) and adaptive (i.e. CD4 and CD8 T cell) immune response upon repeated low dose DEP exposure and downregulation of protective bacteria-induced T cell cytokines (IL-10 and IL-6) and upregulation of macrophage bactericidal cytokines |
| Jaspers I, 2005 | Human | NEC & BEC | DEas | IVA | NEC/BEC cells, following exposure and infection: - IVA m-RNA transcription level, viral proteins; IVA-induced IFN-\(\beta\)-mRNA level, ISRE promoter reporter activity (IFN-stimulated | Increased oxidative stress-mediated (DCF-DA) susceptibility to viral infections is manifested by increase in IVA RNA transcription activity and viral proteins in NEC cells. Increased susceptibility is likely unrelated to IFN-\(\beta\)|
| Case Study | Species | Model | Condition | Outcome |
|------------|---------|-------|-----------|---------|
| Harrod K, 2005 | Mice | In-vivo | BEC, DEE, PAE | BEC, following exposure and infection: - Histopathology severity scores; tissue bacterial count of PAE - Tissue β tubulin (BEC ciliary) marker, epithelial SCGB1A1 (non-ciliated BEC marker i.e. Clara cell) marker, and tissue TTF-1 (lung-specific host defense gene expression/transcription regulator) |
| Hongwei Zhou, 2007 | Mice | In-vitro | BALF PM < 2.5 µm | BALF Mφ, following exposure and infection: - Tissue count of total SP uptake, ingestion, and killing |
| Sigaud S, 2007 | Mice | In-vivo & In-vitro | BALF PM < 2.5 µm | BALF Mφ and PMN, following IFN-γ priming and exposure: - PMN count, DCF-DA (OS marker); lung expressed pro-inflammatory cytokine mRNA |

(continued)
| Author, year      | Clinical Model       | Sample under study | Pollutant | Infectious agent | Outcome measure                                                                 | Clinical Findings                                                                 |
|------------------|----------------------|--------------------|-----------|------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Mushtaq N, 2011  | Human In-vitro       | BEC                | PM < 10 μm| SP               | BEC, following exposure and infection:                                           | PM-enhanced vulnerability to human SP infection in vitro, manifested by increased |
|                  |                      |                    |           |                  | - Adhesion of SP to PM-exposed BEC in-vitro and in-vivo; and glutathione (oxidative| bacterial adhesion and penetration into BEC, mediated by oxidative stress and |
|                  |                      |                    |           |                  | stress marker) level reversal by NAC                                              | PAFR, and reversed by NAC and PAFR blockage                                      |
|                  |                      |                    |           |                  | - PAFR (putative receptor for PM-stimulated pneumococcal adhesion to airway cells) |                                                                                 |
|                  |                      |                    |           |                  | mRNA transcript level, receptor expression, and blocking                         |                                                                                 |
|                  |                      |                    |           |                  |                                                                                   |                                                                                 |
| Chaudhuri N, 2012| Human In-vitro       | Serum MDMφ         | DEP       | E-Coli (LPS endotoxin) | Serum MDMφ, following exposure:                                                   | Loss of low-level DEP-exposed MDMφ along their differentiation into macrophages |
|                  |                      |                    |           |                  | - Cell count of DEP-incorporating MDMφ in COPD and healthy volunteers; MDMφ        | likely due to dysfunctional (loss of mitochondrial membrane electrical potential |
|                  |                      |                    |           |                  | mitochondrial membrane electrical potential and lysosomal fluorescence in healthy | and lysosomal function) and phenotypic (TLR-mediated reduction in CD14 and CD11    |
|                  |                      |                    |           |                  | volunteers                                                                     | surface marker expression) structural changes in MDMφ of healthy exposed       |
|                  |                      |                    |           |                  | Serum MDMφ, following exposure, TLR agonist, and LPS endotoxin:                   | individuals. This can likely contribute to inflammation in COPD by decreased     |
|                  |                      |                    |           |                  | - CXCL8 (Mφ produced IL-8) cytokine responses following TLR4, TLR7 agonists or heat| MDMφ pro-inflammatory cytokines (CXCL8) production.                               |
|                  |                      |                    |           |                  | killed E. coli in both COPD and healthy volunteers; MDMφ CD14 (co-receptor to |                                                                                 |
|                  |                      |                    |           |                  | TLR4 for LPS recognition), CD11b (Mφ differentiation marker) surface marker        |                                                                                 |
|                  |                      |                    |           |                  | expression in healthy volunteers                                                  |                                                                                 |
| Study | Species | Treatment | Controls | Exposure | Measurements | Findings |
|-------|---------|-----------|----------|----------|--------------|----------|
| Migliaccio C, 2013 | Mice | AM & BMdM | WS derived PM or IWS | SP | BALF, following high level IWS and SP infection: - Bacterial load; AM Phagocytosis; IFN-γ production; leucocytes class II” MHC (marker of MO activation), AF (marker of phagocytosis); RelB activation and translocation (NF-κB pathway activity), Cyp1A1 activation (AhR pathway activity) | Impaired antimicrobial defense system with inhalation of high level WS and infection with SP secondary to decrease in IFN-γ production and macrophage number and activation (leucocytes class II” MHC) but not in phagocytic activity (unchanged AF marker), likely mediated via NF-κB pathway activation and AhR pathway. Unchanged phagocytic activity and no increase in neutrophils or TNF-α (data not shown). |
| Zhao H, 2014 | Rats | BALF | PM 2.5 μm | SA | BALF, following exposure: - AM, neutrophils, lymphocytes, and total cells; IL-6 and TNF-α level | PM exposure triggers recruitment of inflammatory cells, secretions of key inflammatory cytokines (IL-6, TNF-α) in BALF and increases susceptibility to SA infection through depressed phagocytosis and abnormal NK cell response, both restored by adoptive transfer of NK cells. |
| Roos A, 2015 | Mice | BALF | CS | NTHi | BALF, following CS exposure and NTHi infection in IL-17⁺ and/or IL-17⁻ (knock out) or IL-1R1⁻ mice: - Neutrophils, total cells, neutrophils count following anti-IL-17A therapy; IL-17 (Th17 pathway) level, CXCL1, and CXCL5 | Following exposure and infection in BALF of IL-17⁺ mice, an increased cell counts of neutrophils, total lymphocytes and IL-17 noted; Important role of IL-17 in inducing NTHi exacerbated neutrophilia of exposed mice stems from attenuation of IL-17 and cell counts in IL-17 “knock out” mice or with suppression of neutrophilia in NTHi infected mice pre-treated with anti-IL-17A antibody; Important role of IL-1 signaling in exacerbating IL-17A-mediated neutrophilia. |
| Author, year | Clinical Model | Sample under study | Pollutant | Infectious agent | Outcome measure | Clinical Findings |
|-------------|----------------|-------------------|-----------|-----------------|-----------------|------------------|
| Rylance J, 2015<sup>169</sup> | Human In-vivo & In-vitro | BALF & Serum | WS PM < 4 μm HAP | E-Coli (LPS endotoxin) | BALF, following natural (household) or experimental (WS) PM exposure or LPS infection and glutathione depletion: - AM phagocytosis, proteolysis (LDH), and oxidative burst; Glutathione (antioxidant marker) response to buthionine sulfoximine (BSO- | Natural (chronic) PM exposure of human BALF decreases AM cytokine (CXCL8) release, downregulates induced phagosomal oxidative burst but does not impair redox potential, proteolysis or phagocytosis. LPS priming following PM ex vivo exposure increased all cytokine (CXCL8, IL-6, TNF-α, CCL2) levels; however, reduction of |
| Study | Species | Model | Airway Surface Fluid (ASF) | Exposure | Outcome | Notes |
|-------|---------|-------|----------------|---------|--------|-------|
| Buonfiglio L, 2017<sup>162</sup> | Pig & Human | NEC, BEC | βPM (CFA) | SA | Pig NEC, ASL/AMP and human BEC, following exposure and infection; and human lysozyme following exposure: - Live bacterial tissue count; - HBD-3 (human β defensin-3), LL-37 (Cathelicidin), and lysozyme (cationic) level (all 3 are components of ASL/AMP); CFA adsorption to Lysozyme; Zeta potential (electrostatic interaction between CFA and lysozyme) | In human and animal model PM-induced impairment of airway antimicrobial activity against SA manifests as decreased levels of HBD-3, LL-37, and free lysozyme level, all components of epithelial air surface liquid antimicrobial proteins, and results from adsorption and electrostatic interactions between pollutants (CFA) or bacteria with ASL AMPs, leading to depletion of the latter thereby increasing the chance of bacterial proliferation. |
| Jaligama S, 2017<sup>172</sup> | Neonatal Mice | LT | DCB (combustion derived PM with EPFR) | IVA | Neonatal LT and Treg following exposure, or exposure and infection, or Treg depletion, or Treg adoptive transfer, or recombinant IL10 (rIL-10) treatment: - IL-10; Treg; IL-10-anti CD25; weight change and pulmonary viral load. | Following IVA infection in neonatal mice, a PM-induced suppression of adaptive immune system is mediated by increase in Treg and IL-10, reversed by Treg depletion and recapitulated by Treg adoptive transfer or rIL-10 treatment. |
| Ma J, 2017<sup>178</sup> | Mouse | BALF | PM2.5 | IVA | BALF following exposure and infection, in normal or in Kdm6a (IFN-β and IL-6 gene expression regulator through respective activation by histone demethylation) knockdown mice: - Mice survival rate; IFN-β and IL-6 levels; OAS1 (IFN-β stimulating gene) expression; Mφ Kdm6a | Short-term (1 day) exposure to PM-inhalation followed by IVA infection results in early phase robust upregulation of IL-6 level and IFN-β level and expression (OAS1), whereas long-term (starting day 3) exposure downregulates innate immune response to IVA infection, likely mediated by macrophage cytokine expression gene regulator, Kdm6a. |

(continued)
| Author, year | Clinical Model | Sample under study | Pollutant | Infectious agent | Outcome measure | Clinical Findings |
|--------------|----------------|--------------------|-----------|-----------------|-----------------|-------------------|
| Zarcone M, 2017<sup>115</sup> | Human In-vitro | PBEC | DEP | NTHi | PBEC following exposure and infection in healthy and COPD patients: - Epithelial barrier activity; LDH (cytotoxicity) release; Epithelial gene expression of OS response markers (heme oxygenase - HO), HSPA5 binding protein (endoplasmic reticulum chaperone), CHOP (marker for ER-stress induced apoptosis) | DEP- and NTHi-mediated acute attacks in COPD patients results in no epithelial barrier dysfunction nor cytotoxicity. It can be induced by increased expression of HO epithelial antioxidant marker and by alterations in epithelial innate immunity undertaken at the level of endoplasmic reticulum and manifested by depressed gene expression, but not apoptosis (CHOP), of integrated stress response markers HSPA5. |
| Bhat T, 2018<sup>175</sup> | Mice Ex-vivo | BALF, LT, & serum | SHS | NTHi | LT, BALF, serum, bone marrow and splenocytes following exposure and infection, and/or P6 vaccination: - Lymphocytic inflammation around broncho-alveolar bundles; DC, neutrophils, and Mφ; CD4<sup>+</sup>CD8<sup>+</sup> B and T cells, RORγT<sup>+</sup> Th17, IL-6, IL-1β, and TNF-α; Anti-P6 (NTHi-derived outer membrane lipoprotein DNA binding protein) total antibodies; Antibodies subclasses IgG1, IgG2a, IgG2b, IgA and Antibody-secreting specific B cells; P6-specific producing Th17 cells, IL-4 and IFN-γ producing T cells, IgG1 and IgG2a subclasses of Anti P6 - secreting B cells; IL-4 and IFN-γ secreting P6-specific T cells; Bacterial clearance, albumin level | SHS exposure and infection impaired bacterial clearance manifested as increase in immune cell infiltrate (Neutrophils, DC, B cells, T cells) except for macrophages, and impeded induction of a robust adaptive immune response manifested as decreased IFN-γ despite increased IL-17, IL-6, IL-1β, TNF-α and RORγ<sup>+</sup> Th17; also, prolonged depression in B cell adaptive immune response manifested as reduced total anti-P6 antibodies and Antibody subclasses (IgA, IgG1, IgG2a IgG2b) Following exposure and (P6-) specific T cell stimulation (vaccination), a decrease in IL-4 and IFN-γ in lung and spleen, both required for Antibody class switching to IgG1 and IgG2a, concomitant with decreased frequency of anti-P6 Ig-secreting B cells for both IgG1 and IgG2 |

<sup>115</sup> Zarcone M, 2017<sup>115</sup> | Human In-vitro | PBEC | DEP | NTHi | PBEC following exposure and infection in healthy and COPD patients: - Epithelial barrier activity; LDH (cytotoxicity) release; Epithelial gene expression of OS response markers (heme oxygenase - HO), HSPA5 binding protein (endoplasmic reticulum chaperone), CHOP (marker for ER-stress induced apoptosis) | DEP- and NTHi-mediated acute attacks in COPD patients results in no epithelial barrier dysfunction nor cytotoxicity. It can be induced by increased expression of HO epithelial antioxidant marker and by alterations in epithelial innate immunity undertaken at the level of endoplasmic reticulum and manifested by depressed gene expression, but not apoptosis (CHOP), of integrated stress response markers HSPA5. |
| Bhat T, 2018<sup>175</sup> | Mice Ex-vivo | BALF, LT, & serum | SHS | NTHi | LT, BALF, serum, bone marrow and splenocytes following exposure and infection, and/or P6 vaccination: - Lymphocytic inflammation around broncho-alveolar bundles; DC, neutrophils, and Mφ; CD4<sup>+</sup>CD8<sup>+</sup> B and T cells, RORγT<sup>+</sup> Th17, IL-6, IL-1β, and TNF-α; Anti-P6 (NTHi-derived outer membrane lipoprotein DNA binding protein) total antibodies; Antibodies subclasses IgG1, IgG2a, IgG2b, IgA and Antibody-secreting specific B cells; P6-specific producing Th17 cells, IL-4 and IFN-γ producing T cells, IgG1 and IgG2a subclasses of Anti P6 - secreting B cells; IL-4 and IFN-γ secreting P6-specific T cells; Bacterial clearance, albumin level | SHS exposure and infection impaired bacterial clearance manifested as increase in immune cell infiltrate (Neutrophils, DC, B cells, T cells) except for macrophages, and impeded induction of a robust adaptive immune response manifested as decreased IFN-γ despite increased IL-17, IL-6, IL-1β, TNF-α and RORγ<sup>+</sup> Th17; also, prolonged depression in B cell adaptive immune response manifested as reduced total anti-P6 antibodies and Antibody subclasses (IgA, IgG1, IgG2a IgG2b) Following exposure and (P6-) specific T cell stimulation (vaccination), a decrease in IL-4 and IFN-γ in lung and spleen, both required for Antibody class switching to IgG1 and IgG2a, concomitant with decreased frequency of anti-P6 Ig-secreting B cells for both IgG1 and IgG2 |

<sup>175</sup> Bhat T, 2018<sup>175</sup> | Mice Ex-vivo | BALF, LT, & serum | SHS | NTHi | LT, BALF, serum, bone marrow and splenocytes following exposure and infection, and/or P6 vaccination: - Lymphocytic inflammation around broncho-alveolar bundles; DC, neutrophils, and Mφ; CD4<sup>+</sup>CD8<sup>+</sup> B and T cells, RORγT<sup>+</sup> Th17, IL-6, IL-1β, and TNF-α; Anti-P6 (NTHi-derived outer membrane lipoprotein DNA binding protein) total antibodies; Antibodies subclasses IgG1, IgG2a, IgG2b, IgA and Antibody-secreting specific B cells; P6-specific producing Th17 cells, IL-4 and IFN-γ producing T cells, IgG1 and IgG2a subclasses of Anti P6 - secreting B cells; IL-4 and IFN-γ secreting P6-specific T cells; Bacterial clearance, albumin level | SHS exposure and infection impaired bacterial clearance manifested as increase in immune cell infiltrate (Neutrophils, DC, B cells, T cells) except for macrophages, and impeded induction of a robust adaptive immune response manifested as decreased IFN-γ despite increased IL-17, IL-6, IL-1β, TNF-α and RORγ<sup>+</sup> Th17; also, prolonged depression in B cell adaptive immune response manifested as reduced total anti-P6 antibodies and Antibody subclasses (IgA, IgG1, IgG2a IgG2b) Following exposure and (P6-) specific T cell stimulation (vaccination), a decrease in IL-4 and IFN-γ in lung and spleen, both required for Antibody class switching to IgG1 and IgG2a, concomitant with decreased frequency of anti-P6 Ig-secreting B cells for both IgG1 and IgG2 |
Sub-classes suggest depressed T cell adaptive immune system essential for inducing robust antibody responses to NTHi infection. P6 Immunization and SHS exposure impaired induction of robust T and B cell mediated immune response when compared to air exposure, increased influx of neutrophils but not bacterial clearance thereby suggesting significant impairment of neutrophils phagocytic function. Consequently, depressed B and T cell adaptive immune response can be mitigated by P6 antigen vaccination.

| Authors | Study Type | Cells | Condition | Exposure | Parameters Measured |
|---------|------------|-------|-----------|----------|---------------------|
| Chen X, 2018 | Human In-vitro | BEC | PM | PAE | BEC, following exposure and infection: - Invasion by PA; Oxidation-sensitive fluorescent probe (DCFH-DA) for ROS formation; SA-β-gal biomarker (cell senescence); hBD-2 (epithelial antimicrobial peptide) level; mRNA expression of hBD-2, lactoferrin, IL-8, and IL-13 |
| Gotts J, 2018 | Mice Ex-vivo | LT, BALF, blood and spleen | CS | SP | BALF, LT and blood following exposure and infection, and/or antibiotic therapy: - Mice lung injury (survival rate, lung weight loss, hypothermia, arterial oxygen saturation, excess extravascular lung water) with brief or severe CS exposure; Neutrophils, lymphocytes, MΦ and monocytes; Chemokines for neutrophils |

PM followed by PAE infection increases epithelial cell senescence biomarker (SA-β-gal) in an ROS-mediated and a concentration-dependent manner and interferes with innate bactericidal response of airway epithelium by suppressing induction of hBD-2 level and mRNA expression, but not lactoferrin, IL-8, or IL-13.

CS improved mice survival on severe exposure but no other parameters of bacterial pneumonia; contributed to confinement of the infection to the lung manifested by a decreased number of neutrophils, increase in MΦ and monocytes but no change in lymphocytes; and caused a differential elevation of neutrophils antimicrobial peptides MPO, but

(continued)
| Author, year | Clinical Model | Sample under study | Pollutant | Infectious agent | Outcome measure | Clinical Findings |
|--------------|----------------|-------------------|-----------|----------------|----------------|------------------|
| Wang W., 2018 | Chicken Ex-vivo | LT | H$_2$S | LPS | Lung tissue following exposure & infection:  
- Histopathology; m-RNA level of IL-4, IL-6 (secreted by Th2), TNF-α, IL-1β, IFN-γ (secreted by Th1), and HO-1 (antioxidant enzyme); m-RNA expression of oxidative stress NF-kB pathway genes (IκB and Iκκα), TNF-α, and PPAR-γ (peroxisome proliferator nuclear receptor) | H$_2$S exposure aggravated LPS-induced inflammatory changes in the lungs through Th1/Th2 imbalance manifested by increased mRNA expression of IL-4, IL-6, IL-1β, and TNF-α expression and a concordant decrease in IFN-γ expression; also by depressed antioxidant mechanisms such as antioxidant enzyme (HO-1) levels and PPAR-γ expression, and by activation of NF-κB pathway-related genes (IκB and Iκκα). |

**Table 2.** (Continued) Outcome findings in IAD clinical models challenged by exposure and infection with reference to biomarkers. **AECOPD** (Acute exacerbation of chronic obstructive pulmonary disease); **AF** (Asthma flare); **AhR** (Aryl hydrocarbon receptor); **AM** (Alveolar macrophages); **AMP** (Antimicrobial proteins and peptides); **ASL** (Airway surface liquid); **BALF** (Bronchoalveolar lavage fluid); **BEC** (Bronchial epithelial cells); **BM** (Bone marrow derived Macrophages); **BSO** (Buthionine sulfoximine); **CCL2** (Chemokine Ligand); **CD** (Cluster of differentiation); **CF** (Coal fly ash); **COPD** (Chronic obstructive pulmonary disease); **CS** (Cigarette Smoke); **CYP1A1** (Cytochrome P450 Family 1 Subfamily A Member 1); **DC** (Dendritic cells); **DE** (Diesel exhaust particles); **E. Coli** (Escherichia coli); **EF** (Environmentally persistent free radicals); **H$_2$S** (Hydrogen sulfide); **HAP** (Heat Shock Protein Family A (Hsp70) Member 5); **ICAM-1** (Intercellular adhesion molecule 1); **IFN** (Immunoglobulin); **IL** (Interleukin); **LPS** (Lipopolysaccharide); **M** (Macrophages); **MDM** (Monocyte-Derived Macrophages); **MIP-1alpha** (Monocyte-Chemotactic Protein-1); **MO** (Monocytes); **MP** (Myeloperoxidase); **mRNA** (Messenger RNA); **Mφ** (Macrophages); **NAC** (N-acetylcysteine); **NEC** (N-acylcycteine); **NF-κB** (Nuclear factor kappa beta); **NIK** (Natural killer); **NO** (Nitric oxide); **NO$_2$** (Nitrogen Dioxide); **NTHI** (Nontypeable Haemophilus influenzae); **O$_3$** (Ozone); **OAS** (Oligoadenylate synthetase); **OS** (Oxidative stress); **P6** (Protein 6); **PAA** (Pseudomonas Aeruginosa); **PAF** (Receptor for platelet-activating factor); **PBEC** (Primary bronchial epithelial cells); **PM** (Particulate matter); **PMN** (Polymorphonuclear leukocyte); **PPAR** (Peroxisome proliferator-activated receptor); **ROR-γ** (Reactive oxygen radicals); **ROS** (Reactive oxygen species); **RV16** (Rhinovirus 16); **SA** (Staphylococcus aureus); **SA-gal** (Senescence-associated β-galactosidase assay); **SCG81A1** (Secretoglobin); **SHS** (Secondhand smoke); **SP** (Streptococcus Pneumonia); **TLRs** (Toll-like receptors); **TNF** (Tumour Necrosis Factor); **Treg** (Regulatory T cells); **TTF1** (Thyroid transcription factor 1); **WS** (Wood smoke)
resulted in increased ICAM 1 receptor expression (receptor for RV16) and pro-inflammatory IL-8 cytokine production.\textsuperscript{71} In another combined human and animal model, activated nasal airway microbial proteins at the surface mucosal liquid, which include lysozyme, human cathelicidin antimicrobial peptide, and human β defensins, were attenuated following (PM) exposure and \textit{Staphylococcus aureus} infection. The ensuing impaired bacterial killing resulted from adsorption and electrostatic interactions between either pollutant or bacteria with activated microbial proteins leading to the depletion of the latter.\textsuperscript{162}

The literature on the lower airways exceeds that on the upper airways. In this respect, susceptibility to infections following exposure was examined at several stages of immunological alterations triggered in host cells.

Starting with the epithelial barrier level, an initial \textit{in vivo} PM exposure of bronchial epithelial cells in mice followed by experimental infection with \textit{Pseudomonas aeruginosa} resulted in decreased levels of an epithelial ciliary marker (β tubulin) and a non-ciliary epithelial (Clara cells) marker, and their gene expression/transcription regulator, all suggesting airway remodeling is a contributing factor to the impaired bacterial clearance.\textsuperscript{163} Furthermore, an initial infection with \textit{Pseudomonas aeruginosa} induced an epithelial antimicrobial peptide human beta defensin 2; but as the model was pre-exposed to PM, induction of human beta defensin 2 was suppressed and a cell senescence biomarker (SA-β-gal) was upregulated in an ROS-dependent process.\textsuperscript{164} Also, in an \textit{in vitro} human model, a PM-enhanced susceptibility to \textit{Streptococcus pneumoniae} infection was heightened by increased bacterial adhesion and penetration into bronchial epithelial cells. This was mediated by a receptor for platelet-activating factor, a putative receptor for PM-stimulated pneumococcal adhesion to airway cells.\textsuperscript{165}

On a submucosal level, macrophages and monocytes play a central role in phagocytosis. The study of immunopathological alterations in phagocytosis has shown inconsistent results. For example, in an exposure (PM)-infectious animal model, impaired \textit{Streptococcus pneumoniae} clearance and phagocytosis resulted from decreased macrophages internalization of bacteria, although increased binding of microbe to surface of macrophages was reported.\textsuperscript{166} In a similar model increased susceptibility to \textit{Staphylococcus aureus} infection resulted from depressed phagocytosis index and abnormal natural killer cell response.\textsuperscript{167} Also, in another animal exposure model increased infectivity to \textit{Listeria monocytogenes} resulted from decreased ROS-induced nitric oxide production by alveolar macrophages.\textsuperscript{168} In contrast, natural (chronic) PM exposure of human bronchoalveolar lavage fluid decreased macrophage cytokine (CXCL8) release and downregulated induced phagosomal oxidative burst. Per contra, no impairment in macrophage redox potential, proteolysis or phagocytosis was observed likely due to the experimental chronicity of exposure.\textsuperscript{169} Additionally, in an analogous model using high levels of the same pollutant (PM), the impaired antimicrobial defense resulted from defective macrophage activation of T cells by class II major histocompatibility complex and subsequent decrease in interferon-γ production, but unaltered phagocytic activity.\textsuperscript{170} Interestingly, no increase of neutrophils and TNF-α levels was observed in bronchoalveolar lavage following exposure and infection suggesting acute exposure to relatively high level of PM does not trigger a classic or sustained inflammatory response.\textsuperscript{170}

Besides suggesting interference with innate immunity, exposure studies suggest further alterations in adaptive immunity as evidenced by immunopathological relationships between antigen presenting cell cytokines, the corresponding sensitized T cells subsets, and recruited neutrophils (see Table 2). As such, a \textit{Listeria monocytogenes}-mediated suppression of macrophages immune response upon low dose DEP exposure manifested as "dysfunctional" production of macrophages-derived cytokines. This was associated with downregulation of innate protective cytokines (e.g. IL-1β, tumor necrosis factor-α, IL-12, IL-2 and interferon-γ), suppression of adaptive CD4 and CD8 T cell immune response, and upregulation of macrophage bactericidal anti-inflammatory cytokines (IL-10 and IL-6).\textsuperscript{171} Other examples of altered cytokine release include the pro-inflammatory
interleukin-8 (IL-8) synergistic release by respiratory cells in an exposure model challenged by viral infection (rhinovirus 16); also a decrease in chemokine ligand 2 level in an experimental PM exposure model involving lipopolysaccharide priming, thereby suggesting an important role of chemokine ligand 2 in preventing excessive inflammation. Besides the role of cytokines in fine tuning extent of inflammation in these models, T cell subsets like T cytotoxic (CD8+) and regulatory T cells (Treg) in addition to neutrophils have been studied. DEP exposure in rats increased susceptibility to Listeria monocytogenes infection by attenuating T cell mediated immunity, namely CD4+ T helper lymphocytes and CD8+ T cytotoxic cells. PM exposure in neonatal mice resulted in depression of adaptive response to influenza virus A infection and by an increased expression in Treg cells and IL-10 in lung tissues. Interestingly, the induced immunosuppressive effect was reversed by Treg depletion and restored by either Treg transfer or recombinant IL-10 treatment.

Furthermore, airway neutrophilia, which is instrumental in bacterial clearance, has been studied in in vitro infectious exposure model in relationship to Th1 and Th17 proinflammatory cytokine release. The concomitant increase in bronchoalveolar lavage fluid IL-17 with airway neutrophilia, and their attenuation in IL-17 “knock out” mice following exposure and infection suggested the importance of IL-17 in inducing neutrophil-mediated airway inflammation. Also, decreased induction of IL-17A-mediated airway neutrophilia following exposure and infection in IL-1R1- mice compared with wild-type controls also suggests IL-1 signaling is required in IL-17A-exacerbated neutrophilia. Moreover, in an in vivo exposure-infectious animal model modulated by interferon-γ priming to mimic viral infection, an impaired PM-mediated bacterial phagocytosis correlated with activation of genes encoding neutrophil-recruiting chemokines and increased histopathology suggestive of severe pneumonia. Still, in an animal in vivo model, exposure followed by LPS infection induced cytokine changes in the lung suggestive of a Th1/Th2 imbalance and manifested by increased expression of IL-4 among others, and a concordant decrease in IFN-γ expression.

The infectious-exposure model is an attractive tool to explore immunopathological alterations in COPD patients or in laboratory cells exposed to secondhand smoking. In a mice model, 8 weeks secondhand smoking pre-exposure was followed by infection with non-typeable Haemophilus influenzae which is a pathogen commonly implicated in acute exacerbation of COPD. The model revealed increased number of immune cell infiltrates except for macrophages, and a suppressed induction of a robust adaptive immune response manifested as decreased IFN-γ. Also, a downregulated T cell adaptive response manifested by decreased bacterial clearance and diminished efficiency of specific antibody subclass switching, both mitigated by anti-viral vaccination. In a similar animal model examining the immunological effect of antibiotic therapy, cigarette smoke exposure followed by Streptococcus pneumoniae infection resulted in recruitment of macrophages and monocytes in lung tissue and alveolar fluid reportedly to confine infection to the lung; also a decreased number of neutrophils but a differential increase in neutrophil-mediated antimicrobial peptide, myeloperoxidase. Antibiotic therapy had no effect on mice survival rate but reduced lung injury and induced a differential change of cytokine levels in bronchoalveolar lavage fluid most importantly downregulation of Th1 and Th17 inflammatory cytokines. Human in-vitro pre-exposure and infectious models are designed to mimic acute exacerbations in stable but exposed COPD patients. DEP exposure followed by non-typeable Haemophilus influenzae infection did not compromise mucosal barrier function in COPD or healthy patients. However, epithelial endoplasmic reticulum activity was markedly disrupted in COPD patients, manifested by depressed gene expression of the integrated stress response markers in an ROS-mediated process. In another model, macrophages differentiating from locally recruited monocytes in lungs of COPD patients were pre-exposed to low level DEP and subsequently challenged with TLR agonists or heat killed E.coli. This resulted in structural and functional changes in innate and adaptive immune system consisting of mitochondrial and lysosomal dysfunction in macrophages.
decreased expression of their surface recognition markers, loss of macrophage differentiation, and reduction in proinflammatory cytokine production (e.g. IL-8). \(^{177}\)

The majority of exposure-infection human and animal models have examined immunological alterations following long-term (weeks) and low-dose pre-exposure periods which best mimics real-life outdoor pollutant exposure or indoor secondhand smoking relevant to COPD. Nevertheless, other models which studied brief and short-term (hours to days) exposure periods have yielded mixed results. For example, one-week diesel exhaust pre-exposure of mice in vivo decreased *Pseudomonas aeruginosa* clearance from bronchial epithelial cells, whereas in the same model a six-months pre-exposure did not. \(^{163}\) Also, in an in vivo model, mice were pre-exposed to PM for 1 day (short term) or 2 weeks (long term), later infection with Influenza virus A and survival rate was assessed over the ensuing 10 days following contamination. Short-term exposure improved mice survival rate and triggered a robust immune response whereas long-term exposure did not, reportedly mediated by macrophage cytokine gene expression regulator Kdm6a. To model secondhand smoking exposure or for recent initiation of active smoking, mice were exposed to brief (2 h per day for 2 days) low dose of side stream cigarette smoke or to prolonged (2.5 weeks) high dose cigarette smoke, respectively, and later inoculated with *Streptococcus pneumonia*. Surprisingly, brief exposure did not show significant survival benefit whereas prolonged exposure in mice did, reportedly due to diminished propagation of bacteria into the systemic circulation during chronic exposure. \(^{176}\)

Finally, in a mice model examining only chronic secondhand smoking exposure and its impact on non-typeable *Haemophilus influenza* antimicrobial response, 8 weeks secondhand smoking pre-exposure, theoretically mimicking mainstream smoking, compromised the ability of host T cell-mediated adaptive immune system to mount an effective response against non-typeable *Haemophilus influenza* infection. \(^{175}\)

Taken together, these models suggest exposure impairs innate and adaptive immunity against airway microbial infections. Limitations inherent to the design of these models compel a careful interpretation of results taking into consideration the response to infectivity of animal host cells, the duration and intensity of pollutant pre-exposure, and the nature of microbial agents used for contamination.

**SUMMARY**

We reviewed evidence for the involvement of oxidative stress pathways and their nature in healthy individuals and patients with inflammatory airway diseases following exposure to a spectrum of important chemical, allergic and infectious air contaminants. When comparing exposure clinical models in patients with AR, CRS, and allergic asthma, the signal and cascade pathways can generate important oxidative and anti-oxidative markers and induce specific changes in adaptive and innate immune system. Thus, exposure can amplify the inflammatory process in patients with AR, CRS, and allergic asthma supporting evidence that, at least in atopic individuals, exposure can increase airway hypersensitivity. When accentuated by an infectious insult, pre-exposure clinical models in patients with inflammatory airway diseases show specific immunopathological alterations at mucosal and submucosal levels of the airway epithelial barrier and ultimately in the adaptive immune system. The resultant increased susceptibility to infection can be due to either increased infectivity of microbial agents or to a ROS-mediated direct effect of pollutant on host immune defense cells.

**FUTURE RESEARCH**

The complex nature and composition of chemical air pollutants and their aerodynamic properties is reflected in conflicting epidemiological and experimental results on exposure and its impact on health. Also, the oxidative stress-mediated immunopathological changes have highlighted important antioxidant markers, which can be therapeutically bio-engineered. Since there is no clear consensus on efficacy of natural or synthetic antioxidants, \(^{125,180,181}\) current research should search for new therapeutic modalities and define the role of currently available ones such as antihistamines, intransal or inhaled steroids, antibiotics and anti-viral vaccination in patients with inflammatory airway diseases challenged by exposure and at times by an infectious process.
All authors agreed to the publication of this work.

**Abbreviations**

AR: Allergic rhinitis; COPD: Chronic obstructive pulmonary disease; CRS: Chronic rhinosinusitis; DEP: Diesel exhaust particles; IAD: Inflammatory airway diseases; IL: Interleukin; ILC: Innate lymphoid cells; NOx: Nitrogen oxides; PAH: Polycyclic aromatic hydrocarbons; PM: Particulate matter; ROS: Reactive oxygen species; TBS: Tobacco smoke; TLR: Toll-like receptors; Treg: Regulatory T cell; VOCs: Volatile organic compounds

**DECLARATIONS**

**Funding source**
Not applicable.

**Human and animal research**
Not applicable.

**Registration of clinical trials**
Not applicable.

**Availability of data and materials**
Not applicable.

**Author contributions**

We attest that all authors contributed significantly to the creation of this manuscript.

- Philip Rouadi and Samar Idriss initiated the work, contributed substantially to the conception and design of the study, the acquisition, analysis, and interpretation of data.

- Philip Rouadi, Samar Idriss, Robert Naclerio, David Peden, and Ignacio Anstotegui wrote the draft and did a critical review of the article and provided final approval of the version to publish.

- Giorgio Walter Canonica, Sandra N. Gonzalez Diaz, Nelson A. Rosario Filho, Juan Carlos Ivancevich, Peter W. Hellings, Margarita Murrieta-Aguttes, Fares H. Zaitoun, Carla Irani, Marilyn R. Karam, and Jean Bousquet reviewed the manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

- Philip Rouadi supervised the manuscript.

**Ethics committee approval**
Not applicable.

**Publication consent**
All authors agreed to the publication of this work.

**Declaration of competing interest**

The authors have nothing to declare relative to this paper.

**Acknowledgements**

This project was initiated by the Rhinitis and Sinusitis Committee of the World Allergy Organization (2018–2019 term).

**Author details**

aDepartment of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon. bJohns Hopkins University Department of Otolaryngology - Head and Neck Surgery, Baltimore, MD, USA. cUNC Center for Environmental Medicine, Asthma, and Lung Biology, Division of Allergy, Immunology and Rheumatology, Department of Pediatrics UNS School of Medicine, USA. dDepartment of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain. eAsthma & Allergy Clinic,Humanitas University & Research Hospital IRCCS, Milano, Italy. fUniversity Autonoma de Nuevo Leon Facultad de Medicina y Hospital Universitario U.A.N.L, Monterrey, NL, c.p. 64460, México. gFederal University of Paraíba, Brazil. hFaculty of Medicine, Universidad del Salvador, Buenos Aires, Argentina and Head of Allergy and Immunology at the Santa Isabel Clinic, Buenos Aires, Argentina. iDepartment of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium. jDepartment of Otorhinolaryngology, Academic Medical Center Amsterdam, The Netherlands - Department Otorhinolaryngology, University Hospital Ghent, Belgium. k8 Rue Pierre Poli, Issy Les Moulineaux, 92130, France. lLAUMC Rizk Hospital, Otolaryngology-Allergy Department, Beirut, Lebanon. mDepartment of Internal Medicine and Infectious Diseases, St Joseph University, Hotel Dieu de France Hospital, Beirut, Lebanon. nDivision of Rheumatology, Allergy and Clinical Immunology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon. oINSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France. pUniversity Versailles St-Quentin-en-Yvelines, France. qAllergy-Centre-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany.

**REFERENCES**

1. Seinfeld JH, Pandis SN. Atmospheric Chemistry and Physics: From Air Pollution to Climate Change. second ed. New York: John Wiley & Sons, Inc.; 2006. https://doi.org/10.1080/00139157.1999.10544295.

2. Bruce N, Adair-Rohani H, Puzzolo E. WHO Guidelines for Indoor Air Quality: Household Fuel Combustion. World Health Organization; 2014. http://www.who.int/indoorair/guidelines/hhfc/en/. Accessed January 17, 2020.

3. Health Effects Institute. State of Global Air 2019. Special Report.. Boston, MA: Heal Eff Inst; 2019

4. 7 Million Premature Deaths Annually Linked to Air Pollution. World Health Organization; 2014. https://www.who.int/mediacentre/news/releases/2014/air-pollution/en/. Accessed January 17, 2020.
5. Liu Y, Pan J, Zhang H, et al. Short-term exposure to ambient air pollution and asthma mortality. Am J Respir Crit Care Med. 2019;200(1):24-32. https://doi.org/10.1164/rccm.201810-1823OC.

6. Meng X, Wang C, Cao D, Wong CM, Kan H. Short-term effect of ambient air pollution on COPD mortality in four Chinese cities. Atmos Environ. 2013;77:149-154. https://doi.org/10.1016/j.atmosenv.2013.05.001.

7. Hamilos DL. Chronic sinusitis: epidemiology and medical management. J Allergy Clin Immunol. 2011;128:693-707. https://doi.org/10.1016/j.jacii.2011.08.004.

8. Murray CS, Simpson A, Custovic A. Allergens, viruses, and asthma exacerbations. Proc Am Thorac Soc. 2004;1:99-104. https://doi.org/10.1513/pats.2306027.

9. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011;128:1165-1174. https://doi.org/10.1016/j.jaci.2011.10.024.

10. Schwartz J, Slater D, Larson TV, Pierson WE, Koenig JQ. Particulate air pollution and hospital emergency room visits for asthma in Seattle. Am Rev Respir Dis. 1993;147:826-831. https://doi.org/10.1164/ajrccm/147.4.826.

11. Spira Cohen A, Chen LC, Kendall M, Lall R, Thurston GD. Personal exposures to traffic-related air pollution and acute respiratory health among bronx school children with asthma. Environ Health Perspect. 2011;119:559-565. https://doi.org/10.1289/ehp.1002653.

12. Jiang XQ, Mei XD, Feng D. Air pollution and chronic airway diseases: what should people know and do? J Thorac Dis. 2016;8:31-40. https://doi.org/10.3978/j.issn.2072-1439.2015.11.50.

13. Garmendia J, Morey P, Bengoechea JA. Impact of cigarette smoke exposure on host-bacterial pathogen interactions. Eur Respir J. 2012;39:467-477. https://doi.org/10.1183/09031936.00061911.

14. Pöschl U. Atmospheric aerosols: composition, transformation, climate and health effects. Angew Chem. 2005;44:7520-7540. https://doi.org/10.1002/anie.200501122.

15. Anderson JO, Thundiyil JG, Stolbach A. Clearing the air: a review of the effects of particulate matter air pollution on human health. J Med Toxicol. 2012;8:166-175. https://doi.org/10.1007/s13181-011-0203-1.

16. Guarneri N, Balmes JR. Outdoor air pollution and asthma. Lancet. 2014;383:1581-1592. https://doi.org/10.1016/S0140-6736(14)60617-6. Outdoor.

17. Mannucci PM, Harari S, Martinelli I, Franchini M. Effects on health of air pollution: a narrative review. Intern Emerg Med. 2015;10:657-662. https://doi.org/10.1007/s11739-015-1276-7.

18. Qian J, Ferro AR, Fowler KR. Estimating the resuspension rate and residence time of indoor particles. J Air Waste Manag Assoc. 2008;58:502-516. https://doi.org/10.1080/1047-3289.58.4.502.

19. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311:622-627. https://doi.org/10.1126/science.1114397 (80-).

20. Li N, Georas S, Alexis N, Fritz P, Xia T, Williams MS. A work group report on ultrafine particles (AAAP) why ambient ultrafine and engineered nanoparticles should receive special attention for possible adverse health outcomes in humans. J Allergy Clin Immunol. 2016;138:386-396. https://doi.org/10.1016/j.jaci.2016.02.023.A.

21. Falcon-Rodriguez CI, Osornio-Vargas AR, Sada-Ovalle I, Segura-Medina P. Aeroparticles, composition, and lung diseases. Front Immunol. 2016;7:1-9. https://doi.org/10.3389/fimmu.2016.00003.

22. Song X, Liu Y, Hu Y, Zhao X, Tian J, Ding G. Short-term exposure to air pollution and cardiac arrhythmia: a meta-analysis and systematic review. Int J Environ Res Publ Health. 2016;13(642):1-12. https://doi.org/10.3390/ijerph13070642.

23. Du Y, Xu X, Chu M, Guo Y, Wang J. Air particulate matter and cardiovascular disease: the epidemiological, biomedical and clinical evidence. J Thorac Dis. 2016;8(1):8-19. https://doi.org/10.3397/jsth.2015.11.37.

24. Brook RD, Rajagopalan S, lii CAP, et al. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American heart association. Circulation. 2010;121:2331-2378. https://doi.org/10.1161/CIR.0b013e3181dbee1.

25. Brugha R, Grigg J. Urban air pollution and respiratory infections. Paediatr Respir Rev. 2014;15:194-199. https://doi.org/10.1016/j.pirv.2014.03.001.

26. Korpi A, Järnborg J, Pasanen A. Microbial volatile organic compounds. Crit Rev Toxicol. 2009;39:139-193. https://doi.org/10.1080/10408440802291497.

27. Vaughan TL, Stewart PA, Teschke K, et al. Occupational exposure to formaldehyde and wood dust and nasopharyngeal carcinoma. Occup Environ Med. 2000;57:376-384. https://doi.org/10.1136/oem.57.6.376.

28. Zhang L, Freeman LEB, Nakamura J, et al. Formaldehyde and leukemia: epidemiology, potential mechanisms and implications for risk assessment. Environ Mol Mutagen. 2010;51:181-191. https://doi.org/10.1002/em.20534. Formaldehyde.

29. Destailhats H, Maddalena RL, Singer BC, Hodgson AT, Mckone TE. Indoor pollutants emitted by office equipment: a review of reported data and information needs. Atmos Environ. 2008;42:1371-1388. https://doi.org/10.1016/j.atmosenv.2007.10.080.

30. Wolkoff P. Volatile organic compounds - sources, measurements, emissions, and the impact on indoor air quality. Int J Indoor Air Qual Clim. 1995;(Suppl 3):9-73.

31. Yu C, Crump D. A review of the emission of VOCs from polymeric materials used in buildings. Build Environ. 1998;33:357-374. https://doi.org/10.1016/S0360-1323(97)00055-3.

32. Wady L, Bunte A, Pehrson C, Larsson L. Use of gas chromatography-mass spectrometry/solid phase microextraction for the identification of MVOCs from moldy building materials. J Microbial Methods. 2003;52:325-332. doi:0167-7012/02/$.

33. Su F-C, Mukherjee B, Batterman S. Determinants of personal, indoor and outdoor VOC concentrations: an analysis of the RIOPA data. Environ Res. 2013;126:192-203. https://doi.org/10.1016/j.envres.2013.08.005.

34. Lin T, KrishnaSwamy G, Chi DS. Incense smoke: clinical, structural and molecular effects on airway disease. Clin Mol Allergy. 2008;6:1-9. https://doi.org/10.1186/1476-7961-6-3.

35. Lin T, KrishnaSwamy G, Chi DS. Incense smoke: clinical, structural and molecular effects on airway disease. Clin Mol Allergy. 2008;6:1-9. https://doi.org/10.1186/1476-7961-6-3.
Environment the effects of outdoor and indoor dust exposure on the growth, sensitivity to oxidative-stress, and biofilm production of three opportunistic bacterial pathogens. *Sci Total Environ.* 2015;538:949-958. https://doi.org/10.1016/j.scitotenv.2015.08.063.

66. Forrester SJ, Kikuchi DS, Hernandez MS, Xu Q, Griendling KK. Reactive oxygen species in metabolic and inflammatory signaling. *Circ Res.* 2018;122:877-902. https://doi.org/10.1161/CIRCRESAHA.117.311401.

67. Lodovici M, Bigagli E. Oxidative stress and air pollution exposure. *J Toxicol.* 2011:1-9. https://doi.org/10.1155/2011/487074. Review.

68. Dayem AA, Hossain MK, Lee S Bin, et al. The role of reactive oxygen species (ROS) in the biological activities of metallic nanoparticles. *Int J Mol Sci.* 2017;18:1-21. https://doi.org/10.3390/ijms18010120.

69. Cho H, Kleeberger SR. Nrf2 protects against airway disorders. *J Allergy Clin Immunol.* 2013;131:106-116. https://doi.org/10.1016/j.jaci.2013.07.028.

70. Wang J, Li B, Yu W, et al. Rhinitis symptoms and asthma among parents of preschool children in relation to the home environment in chongqing, China. *PloS One.* 2014;9:1-12. https://doi.org/10.1371/journal.pone.0094731.
Med. 2014;21:760-766. https://doi.org/10.5604/12321966.1129929.

93. Gruzieva O, Gehring U, Aalberse R, et al. Meta-analysis of air pollution exposure association with allergic sensitization in European birth cohorts. J Allergy Clin Immunol. 2014;133:767-776. https://doi.org/10.1016/j.jaci.2013.07.048.

94. Hassoun Y, James C, Bernstein DI. The effects of air pollution on the development of atopic disease. Clin Rev Allergy Immunol. 2019;57:403-414. https://doi.org/10.1007/s12016-019-08730-3.

95. Anderson HR, Ruggles R, Pandey KD, et al. Ambient particulate pollution and the world-wide prevalence of asthma, rhinoconjunctivitis and eczema in children: phase One of the International Study of Asthma and Allergies in Childhood (ISAAC). Occup Environ Med. 2010;67:293-300. https://doi.org/10.1136/oem.2009.048785.

96. Cho DY, Nayak JV, Bravo DT, et al. Expression of dual oxidases and secreted cytokines in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013;3:376-383. https://doi.org/10.1002/air.21133.

97. Yu Z, Wang Y, Zhang J, et al. Expression of heme oxygenase-1 in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps: modulation by cytokines. Int Forum Allergy Rhinol. 2015;5:734-740. https://doi.org/10.1002/air.21530.

98. Hong Z, Guo Z, Zhang R, et al. Airborne fine particulate matter induces oxidative stress and inflammation in human nasal epithelial cells. Tohoku J Exp Med. 2016;239:117-125. https://doi.org/10.1620/tjem.239.117.

99. Saxon A, Diaz-sanchez D. Diesel exhaust as a model xenobiotic in allergic inflammation. Immunopharmacology. 2000;48:325-327. https://doi.org/10.1016/S0162-3109(00)00234-4.

100. Ellis Anne K, Murrieta-Aguettes Margarita, Furey Sandy, Carlsden Christopher. Phase 3, single-center, sequential and parallel group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra/Telfast) versus placebo in subjects suffering from Allergic Rhinitis with symptoms aggravated in presence of pollutants: analysis of individual symptom scores. World Allergy Organ J. 2020;13, 100137.

101. Hernandez ML, Dhingra R, Burbank AJ, et al. Low-level ozone has both respiratory & systemic effects in African-American adolescents with asthma despite asthma controller therapy. J Allergy Clin Immunol. 2018;142:1974-1977. https://doi.org/10.1016/j.jaci.2018.08.003. Low-level.

102. Hernandez ML, Lay JC, Harris B, et al. Atopic asthmatic subjects but not atopic subjects without asthma have enhanced inflammatory response to ozone. J Allergy Clin Immunol. 2010;126:537-545. https://doi.org/10.1016/j.jaci.2010.06.043.

103. Christian DL, Chen LL, Scannell CH, Ferrando RE, Welch BS, Balmes JR. Ozone-induced inflammation is attenuated with multiday exposure. Am J Respir Crit Care Med. 1998;158:532-537. https://doi.org/10.1164/ajccm.158.2.9709023.

104. Peden DB, Boehlecke B, Horstman D, Devlin R. Prolonged acute exposure to 0.16 ppm ozone induces eosinophilic airway inflammation in asthmatic subjects with allergies. J Allergy Clin Immunol. 1997;100:802-808. https://doi.org/10.1016/S0091-6749(97)70277-X.

105. Hernandez M, Brickey WJ, Alexis NE, et al. Airway cells from atopic asthmatics exposed to ozone display an enhanced innate immune gene profile. J Allergy Clin Immunol. 2012;129:259-261. https://doi.org/10.1016/j.jaci.2011.11.007. Airway.

106. Grzioui C, Rovina N, Makris M, Simoes DCM, Papapetropoulos A, Roussos C. Breath markers of oxidative stress and airway inflammation in seasonal allergic rhinitis. Int J Immunopathol Pharmacol. 2008;21:949-957.

107. Sagdic A, Sener O, Bulucu F, et al. Oxidative stress status and plasma trace elements in patients with asthma or allergic rhinitis. Allergol Immunopathol (Madr). 2011;39:200-205. https://doi.org/10.1016/j.aller.2010.07.006.

108. Emin O, Hasan A, Aysenugl D, Rusen D. Total antioxidant status and oxidative stress and their relationship to total IgE levels and eosinophil counts in children with allergic rhinitis. J Investig Allergol Clin Immunol. 2012;22:188-192. https://doi.org/10.1177/03943200802100419.

109. Ozkaya E, Akduman MDH, Erenberk U, Demir A, Dundarov MR. Plasma paraoxonase activity and oxidative stress and their relationship to disease severity in children with allergic rhinitis. J Rhinol Allergy. 2013;27:13-18. https://doi.org/10.2500/ajra.2013.27.3837.

110. Ulusoy S, Ayan NN, Dinc ME, Is A, Bicer C, Erol O. A new oxidative stress marker for thiol-disulphide homeostasis in seasonal allergic rhinitis. J Rhinol Allergy. 2016;30:53-57. https://doi.org/10.2500/ajra.2016.30.4308.

111. Celik M, Tuncer A, Soyer OU, Sackesen C, Besler HT, Kalayci O. Oxidative stress in the airways of children with asthma and allergic rhinitis. Pediatr Allergy Immunol. 2012;23:556-561. https://doi.org/10.1111/j.1399-3038.2012.01294.x.

112. Elhini A, Abdelwahab S, Ikeda K. Heme oxygenase (HO)-1 is upregulated in the nasal mucosa with allergic rhinitis. Laryngoscope. 2006;116:446-450. https://doi.org/10.1097/01.mlg.0000194692.51979.d1.

113. Moon JH, Kim TH, Lee HM, et al. Overexpression of the superoxide anion and NADPH oxidase isoforms 1 and 4 (NOX1 and NOX4) in allergic nasal mucosa. Am J Rhinol Allergy. 2009;23:370-376. https://doi.org/10.2500/ajra.2009.23.3340.

114. Sadowska-woda I, Bieszcad-bedrejczuk E, Rachel M. Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis. Eur J Pharmacol. 2010;640:197-201. https://doi.org/10.1016/j.ejphar.2010.04.060.

115. Zarcone MC, Schadewijk A Van, Duistermaat E, Hiemstra PS, Kooter IM. Diesel exhaust alters the response of cultured primary bronchial epithelial cells from patients with chronic obstructive pulmonary disease (COPD) to non-typeable Haemophilus influenzae. Respir Res. 2017;18:1-11. https://doi.org/10.1186/s12931-017-0510-4.

116. Yang IA, Fong KM, Zimmerman PV, Holgate ST, Holloway JW. Genetic susceptibility to the respiratory effects of air pollution. Thorax. 2008;63:555-563. https://doi.org/10.1136/thx.2007.079426.

117. Cao T, Xu N, Wang Z, Liu H. Effects of glutathione S-transferase gene polymorphisms and antioxidant capacity per unit albumin on the pathogenesis of chronic obstructive
pulmonary disease. *Oxid Med Cell Longev.* 2017;2017. https://doi.org/10.1155/2017/6232397.

118. Braskett M, Riedl MA. Novel antioxidant approaches to the treatment of upper airway inflammation. *Curr Opin Allergy Clin Immunol.* 2010;10:34-41. https://doi.org/10.1097/ACI.0b013e32833fe613.

119. Decramer M, Mölken MR, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. *Lancet.* 2005;366:1552-1560. https://doi.org/10.1016/S0140-6736(05)67378-3.

120. Rosenlund H, Magnusson J, Kull I, et al. Antioxidant intake and allergic disease in children. *Clin Exp Allergy.* 2012;42:1491-1500. https://doi.org/10.1111/j.1365-2222.2012.04053.x.

121. Bakshaei M, Jabbari F, Hoseini S, et al. Effect of silymarin in the treatment of allergic rhinitis. *Otolaryngol Head Neck Surg.* 2011;145:904-909. https://doi.org/10.1177/0194599811423504.

122. Salve VT, Atram JS. N-Acetylcysteine combined with home based physical activity: effect on health related quality of life in stable COPD patients- a randomised controlled trial. *J Clin Diagn Res.* 2016;10:16-19. https://doi.org/10.7860/JCDR/2016/23668.9890.

123. London NR, Tharanan A, Rule AM, Lane AP, Biswal S, Ramanathan M. Air pollutant-mediated disruption of sinonasal epithelial cell barrier function is reversed by activation of the Nrf2 pathway. *J Allergy Clin Immunol.* 2016;138:1736-1738. https://doi.org/10.1016/j.jaci.2016.06.027.

124. Zaknun D, Schrocksnadel S, Kurz K, Fuchs D. Potential role of antioxidant food supplements, preservatives and colorants in the pathogenesis of allergy and asthma. *Int Arch Allergy Immunol.* 2012;157:113-124. https://doi.org/10.1159/000329137.

125. Moreno-Macias H, Romieu I. Effects of antioxidant supplements and nutrients on patients with asthma and allergies. *J Allergy Clin Immunol.* 2014;133:1237-1244. https://doi.org/10.1016/j.jaci.2014.03.020.

126. Guibas GV, Spandou E, Meditskou S, Vyzzantiadis TA, Priftis KN, Anogianakis G. N-acetylcysteine exerts therapeutic action in a rat model of allergic rhinitis. *Int Forum Allergy Rhinol.* 2013;3:543-550. https://doi.org/10.1002/iarl.21145.

127. Desqueyrroux H, Pujet JC, Prosper M, Squinazi F, Mornas I. Short-term effects of low-level air pollution on respiratory health of adults suffering from moderate to severe asthma. *Environ Res.* 2002;89:29-37. https://doi.org/10.1006/er.2002.4357.

128. Jacquemin B, Kauffmann F, Pin I, et al. Air pollution and environment of asthma. *J Epidemiol Community Health.* 2002;89:29-37. https://doi.org/10.1136/jech.2010.130229.

129. Dusseldorp A, Kruize H, Runekreef B, Hofschreuder P, de Meer G, van Oudvorst AB. Associations of PM10 and airborne iron with respiratory health of adults living near a steel factory. *Am J Respir Crit Care Med.* 1995;152:1932-1939.

130. Von Klot S, Wölke G, Tuch T, et al. Increased asthma medication use in association with ambient fine and ultrafine particles. *Eur Respir J.* 2002;20:691-702. https://doi.org/10.1183/09031936.02.01402001.

131. Horvath I, Loukides S, Wodehouse T, Kharitonov SA, Cole PJ, Barnes PJ. Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. *Thorax.* 1998;53:867-870. https://doi.org/10.1136/thx.53.10.867.

132. Isaxon C, Dierschke K, Pagels JH, et al. Realistic indoor nano-aerosols for a human exposure facility. *J Aerosol Sci.* 2013;60:55-66. https://doi.org/10.1016/j.jaerosci.2013.02.003.

133. Hagerman I, Isaxon C, Gudmundsson A, et al. Effects on heart rate variability by artificially generated indoor nano-sized particles in a chamber study. *Atmos Environ.* 2014;88:165-171. https://doi.org/10.1016/j.atmosenv.2014.02.003.

134. Fiedler N, Laumbach R, Kelly-mcnearl P, et al. Health effects of a mixture of indoor air volatile organics, their ozone oxidation products, and stress. *Environ Health Perspect.* 2005;113:1542-1549. https://doi.org/10.1289/ehp.8132.

135. Fiedler N, Kipen H, Ohman-strickland P, et al. Sensory and cognitive effects of acute exposure to hydrogen sulfide. *Environ Health Perspect.* 2008;116:78-85. https://doi.org/10.1289/ehp.10531.

136. Prah JD, Case MW, Goldstein GM. 1998 equivalence of sensory responses to single and mixed volatile organic compounds at equimolar concentrations. *Environ Health Perspect.* 1998;106:739-744. https://doi.org/10.1289/ehp.9810679.

137. Koren HS, Graham DE, Devlin RB. Exposure of humans to a volatile organic mixture . III . Inflammatory response. *Arch Environ Health.* 1992;47:39-44. https://doi.org/10.1080/00039896.1992.993594.

138. Laumbach RJ, Fiedler N, Gardner CR, et al. Nasal effects of a mixture of volatile organic compounds and their ozone oxidation products. *J Occup Environ Med.* 2005;47:1182-1189. https://doi.org/10.1097/jom.0000183338.95778.f0.

139. Alexis NE, Lay JC, Hazucha M, et al. Low-level ozone exposure induces airways inflammation and modifies cell surface phenotypes in healthy humans. *Inhal Toxicol.* 2010;22(7):593-600. https://doi.org/10.3109/08958371003596587.

140. Kim CS, Alexis NE, Rappold AG, et al. Lung function and inflammatory responses in healthy young adults exposed to 0.06 ppm ozone for 6.6 hours. *Am J Respir Crit Care Med.* 2011;183:1215-1221. https://doi.org/10.1164/rccm.201011-1813OC.

141. Alexis NE, Lay JC, Zhou H, et al. The Glutathione-S-Transferase null genotype and increased neutrophil response to low level ozone (0.06ppm). *J Allergy Clin Immunol.* 2013;131(2):610-612. https://doi.org/10.1016/j.jaci.2012.07.005.

142. Gong H, Linn WS, Clark KW, et al. Exposures of healthy and asthmatic volunteers to concentrated ambient ultrafine particles in los angeles. *Inhal Toxicol.* 2008;20:533-545. https://doi.org/10.1080/08958370801911340.

143. Diaz-Sanchez D, Penichet-Garcia M, Saxon A. Diesel exhaust particles directly induce activated mast cells to degranulate...
and increase histamine levels and symptom severity, J Allergy Clin Immunol. 2000;106:1140-1146. https://doi.org/10.1067/mai.2000.111144.

144. Bauer RN, Diaz-Sanchez D, Jaspers I. Effects of air pollutants on innate immunity: the role of Toll-like receptors and nucleotide-binding oligomerization domain – like receptors. J Allergy Clin Immunol. 2012;129:14-24. https://doi.org/10.1016/j.jaci.2011.01.004.

145. Aberdein JD, Cole J, Bewley MA, Marriott HM, Dockrell DH. The role of innate lymphoid cells in airway in pulmonary hosts defence-the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing. Clin Exp Immunol. 2013;174:193-202. https://doi.org/10.1111/cei.12170.

146. Morgan DJ, Casulli J, Chew C, et al. Innate immune cell suppression and the link with secondary lung bacterial pneumonia. Front Immunol. 2018;9:1-18. https://doi.org/10.3389/fimmu.2018.02943.

147. Mjöberg J, Spits H. Human innate lymphoid cells. J Allergy Clin Immunol. 2016;138:1265-1276. https://doi.org/10.1016/j.jaci.2016.09.009.

148. Krohn IK, Bal SM, Golebski K. The role of innate lymphoid cells in airway inflammation: evolving paradigms. Curr Opin Pulm Med. 2017;24:11-17. https://doi.org/10.1097/MCP.0000000000000435.

149. Ganesan S, Comstock AT, Sajjan US. Barrier function of particulate matter in the spreading of COVID-19 in northern Italy: first evidence-based research hypotheses. medRxiv. 2020. https://doi.org/10.1101/2020.04.11.20061713.

150. Ganesan S, Comstock AT, Sajjan US. Barrier function of particulate matter of Bergamo in Northern Italy: first preliminary evidence. medRxiv. 2020. https://doi.org/10.1101/2020.04.15.20065995, 2020.04.15.20065995.

151. Ogen Y. Assessing nitrogen dioxide (NO2) levels as a contributing factor to the coronavirus (COVID-19) fatality rate. Sci Total Environ. 2020. https://doi.org/10.1016/j.scitotenv.2020.138605.

152. Travaglio M, Popovic R, Yu Y, Leal N, Martins LM. Links between air pollution and COVID-19 in England. medRxiv. 2020. https://doi.org/10.1101/2020.04.16.20067405.

153. Neupane B, Jerrett M, Burnett RT, Marrie T, Arain A, Loeb M. The role of particulate matter found on particulate matter of Bergamo in Northern Italy: first evidence-based research hypotheses. medRxiv. 2020. https://doi.org/10.1101/2020.04.11.20061713.

154. Lightfoot J, Bewley MA, Marriott HM, Dockrell DH. The role of innate lymphoid cells in airway in pulmonary hosts defence-the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing. Clin Exp Immunol. 2013;174:193-202. https://doi.org/10.1111/cei.12170.

155. Aberdein JD, Cole J, Bewley MA, Marriott HM, Dockrell DH. The role of innate lymphoid cells in airway in pulmonary hosts defence-the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing. Clin Exp Immunol. 2013;174:193-202. https://doi.org/10.1111/cei.12170.

156. Mansour R, Comstock AT, Sajjan US. Barrier function of particulate matter of Bergamo in Northern Italy: first preliminary evidence. medRxiv. 2020. https://doi.org/10.1101/2020.04.15.20065995, 2020.04.15.20065995.

157. Travaglio M, Popovic R, Yu Y, Leal N, Martins LM. Links between air pollution and COVID-19 in England. medRxiv. 2020. https://doi.org/10.1101/2020.04.16.20067405.
172. Jaligama S, Saravia J, You D, et al. Regulatory T cells and IL10 suppress pulmonary host defense during early-life exposure to radical containing combustion derived ultrafine particulate matter. *Respir Res*. 2017;18:1-14. https://doi.org/10.1186/s12931-016-0487-4.

173. Roos AB, Sethi S, Nikota J, et al. IL-17A and the promotion of neutrophilia in acute exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2015;192:428-437. https://doi.org/10.1164/rccm.201409-1689OC.

174. Sigaud S, Goldsmith CW, Zhou H, Yang Z, Imrich A, Kobzik L. Air pollution particles diminish bacterial clearance in the primed lungs of mice. *Toxicol Appl Pharmacol*. 2007;223:1-9. https://doi.org/10.1016/j.taap.2007.04.014.

175. Bhat TA, Kalathil SQ, Bogner PN, et al. Secondhand smoke induces inflammation and impairs immunity to respiratory infections. *J Immunol*. 2018;200:2927-2940. https://doi.org/10.4049/jimmunol.1701417. Secondhand.

176. Gotts JE, Chun L, Abbott J, et al. Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice. *Am J Physiol Lung Cell Mol Physiol*. 2018;315:25-40. https://doi.org/10.1152/ajplung.00405.2017.

177. Chaudhuri N, Jary H, Lea S, et al. Diesel exhaust particle exposure in vitro alters monocyte differentiation and function. *PloS One*. 2012;7:1-12. https://doi.org/10.1371/journal.pone.0051107.

178. Ma J, Song S, Guo M, et al. Biochemical and Biophysical Research Communications down-regulating pulmonary macrophage Kdm6a and mediates histones modification in IL-6 and IFN-β promoter regions. *Biochem Biophys Res Commun*. 2017;493:1122-1128. https://doi.org/10.1016/j.bbrc.2017.09.013.

179. Yao H, Edirisinghe I, Rajendrasozhan S, et al. Cigarette smoke-mediated inflammatory and oxidative responses are strain-dependent in mice. *Am J Physiol Lung Cell Mol Physiol*. 2008;294:1174-1186. https://doi.org/10.1152/ajplung.00439.2007.

180. Kurutas EB. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state. *Nutr J*. 2016;15:1-22. https://doi.org/10.1186/s12937-016-0186-S.

181. Stanner SA, Hughes J, Kelly CNM, Buttriss J. A review of the epidemiological evidence for the ‘antioxidant hypothesis. *Publ Health Nutr*. 2003;7:407-422. https://doi.org/10.1079/PHN2003543.